Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Pathogenesis of human immunodeficiency virus infectionHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designMonoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat seraCharacterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeysThe C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsIdentification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positioAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloRole of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionThe highly conserved aspartic acid residue between hypervariable regions 1 and 2 of human immunodeficiency virus type 1 gp120 is important for early stages of virus replication.Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid)Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoproteinPresentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domainsProbing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
P2860
Q24531479-2B5CB7CF-6B9E-4396-8954-4F6B001553C3Q24634681-C0C13C7A-7FF2-46BC-9A6B-35721198ADACQ24679395-D9736584-92A2-4A57-869A-D27EAD8BAF38Q28345448-EDBAB8B7-3C7D-4F2F-940A-E40537E3C0B4Q28646835-5663B605-EC4D-4563-A7BF-1C5E7B6045F9Q29619512-8452BD26-F61B-49B2-95B7-90B4238AB0CCQ30425683-3664B782-2787-4AE6-9129-1A783F8CDBA7Q31143293-41BB7856-D7E8-456D-8214-F4E8A49BC08EQ33783763-D6E02090-A4A3-45DE-8E21-43E2DBB16D54Q33785114-86743B76-63A6-409C-B216-9E801C96ADE8Q33788792-7A06E018-8EEB-47D0-A05E-B6E534646CB0Q33814693-145EDD58-11B0-460B-9C11-FC4062119E09Q33821658-904BB22F-FB8B-466C-A670-433D6FC5F863Q34292765-09390282-B2DE-4329-81B9-EAC5D5ABBEACQ34302085-DA00FC63-2E17-416A-8458-3227ED7512B0Q34406977-DA8AB4CF-F8E5-4763-9318-88E62D35F2B1Q34583767-3B448062-4B85-4826-92D0-B685E178A1C6Q35024202-5C528C96-112E-4DEE-B6EA-6194CAE6AEAAQ35635163-021338E6-88CC-40F8-9AF2-DF1EB4425E8AQ35830393-5A14110D-BFBB-4490-9B14-F93D86C8616DQ35837553-0167C599-B8CF-437B-BAE9-695FEE5A8739Q35838430-867EF6A4-9306-4151-B181-CF5C6B3E94FDQ35838613-35EEC3A2-20C5-4E11-AEF1-56BABE50B0C6Q35845976-31D2E2EC-22B0-4AB5-9044-8DAC683307C7Q35857331-3701C1AF-A734-4E65-AD04-E1B9832B2F69Q35857683-B241DE29-1221-4887-86AE-E47972EDC1BBQ35873306-559A98A7-A069-40E8-A6E6-346021625F4CQ35896178-82623942-0248-410E-BA9B-C881B2ADA0C1Q36365085-2D6DA284-830E-42A4-9765-B780497D92E5Q36366296-32DBBB74-330D-41C6-A303-227C19F85C2AQ36549382-650E3806-DFDF-41C2-B1A1-E6CEAABB55DFQ36620087-61C820A3-CDCC-4B7E-9BBC-5807B70E7B21Q36620408-181EB16C-C784-4DF2-B506-434BC55BBD44Q36626451-E8F2BC27-207B-450D-B624-E34F35468B14Q36626986-337619AF-5010-4628-9ED8-91989911FCB7Q36628256-CD4CF042-FC89-4F0E-92AA-4D4561EA86AEQ36633402-3652FD3C-168F-4491-98FA-052AB61CADF4Q36635175-21B1FF1F-14C0-42C0-9E35-2BE3CC36BFE4Q36636293-513D9149-9059-4AED-B4BC-ED3833EBFB61Q36638240-A82003C3-04A5-4E8F-9B8D-67B698551719
P2860
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Another discontinuous epitope ...... fied by a monoclonal antibody.
@en
Another discontinuous epitope ...... fied by a monoclonal antibody.
@nl
type
label
Another discontinuous epitope ...... fied by a monoclonal antibody.
@en
Another discontinuous epitope ...... fied by a monoclonal antibody.
@nl
prefLabel
Another discontinuous epitope ...... fied by a monoclonal antibody.
@en
Another discontinuous epitope ...... fied by a monoclonal antibody.
@nl
P2093
P2860
P356
P1476
Another discontinuous epitope ...... fied by a monoclonal antibody.
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.20.8949
P407
P577
1991-10-01T00:00:00Z